Back to today’s briefing

Story perspectives

Amgen Q4 Revenues Skyrocket to $9.1 Billion Despite Challenges

2/6/2025

37 3

Summary

Story summary

Amgen's fourth-quarter 2024 revenues soared to $9.1 billion, surpassing forecasts, while full-year earnings reached $33.4 billion—a remarkable 19% jump. Although the company grapples with pipeline hurdles, including a clinical hold on obesity drug AMG 513, hope shines through with the promising bispecific molecule MariTide, set to enter new trials shortly.

1 of 1

Story summary

Amgen's fourth-quarter 2024 revenues soared to $9.1 billion, surpassing forecasts, while full-year earnings reached $33.4 billion—a remarkable 19% jump. Although the company grapples with pipeline hurdles, including a clinical hold on obesity drug AMG 513, hope shines through with the promising bispecific molecule MariTide, set to enter new trials shortly.